Skip to Main Content
An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia.

Authors

Frost E, Hofmann JN, Huang WY, Frazer-Abel AA, Deane KD, Berndt SI

Affiliations

  • Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. berndts@mail.nih.gov.

Abstract

Immune dysregulation is thought to contribute to chronic lymphocytic leukemia (CLL) risk, but biological mechanisms are unclear. We discovered that increased serum levels of B-cell activating factor (BAFF), an important regulator of B-cell maturation, were associated with a decreased risk of CLL, even >10 years after blood draw. Our findings suggest that BAFF could be a useful biomarker to assess risk among individuals at high risk, such as those with monoclonal b-cell lymphocytosis.

Back to Publication Search

Publication Details

PubMed ID
39112445

Digital Object Identifier
10.1038/s41408-024-01106-7

Publication
Blood Cancer J. 2024 Aug 7; Volume 14 (Issue 1): Pages 132

Related CDAS Studies Related CDAS Studies